Answers are grounded in this paper and cite their sources.
Acute kidney injury (AKI) is a common clinical problem with high morbidity and mortality due to frequently occurring secondary organ complications, including acute neurologic dysfunction, such as delirium. Specific mechanisms responsible for this kidney-brain crosstalk are unknown but hypothesized to include uremic toxins and neuroinflammation secondary to systemic inflammation. Here we show that uremic mice with AKI show hippocampal monocytic neuroinflammation associated with acute delirium-like neurologic dysfunction only in the presence of circulating osteopontin fragments. Mechanistically, circulating osteopontin (OPN/Spp1) released by the injured kidney was cleaved by thrombin in the lung into OPN-N and OPN-C-terminal fragments. Both OPN fragments were required to drive upregulation of the monocyte chemoattractant chemokine-ligand-2 (CCL2) in hippocampal endothelial cells. AKI mice lacking OPN or unable to activate OPN by thrombin cleavage showed kidney injury and serum uremic toxin elevations like wt controls but were protected from hippocampal CCL2 upregulation, monocyte recruitment, and delirium-like symptoms. Systemic application of an OPN or CCL2 neutralizing antibody was protective. Our results suggest that a specific kidney-released circulating factor, osteopontin, drives acute neurologic dysfunction after AKI and challenge the widely held hypothesis that uremic toxins play a dominant role. They also identify thrombin cleavage of OPN as a potential therapeutic target and critical switch for the remote functions of circulating OPN.
No takes yet. Share an insight, caveat, or question.
Mudiyanselage et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: